Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities Publisher Pubmed



Farjadian F¹ ; Ghasemi A^{2, 3} ; Gohari O² ; Roointan A⁴ ; Karimi M^{5, 6, 7} ; Hamblin MR^{7, 8, 9} Show Affiliations
Source: Nanomedicine Published:2019

Abstract

There has been a revolution in nanotechnology and nanomedicine. Since 1980, there has been a remarkable increase in approved nano-based pharmaceutical products. These novel nano-based systems can either be therapeutic agents themselves, or else act as vehicles to carry different active pharmaceutical agents into specific parts of the body. Currently marketed nanostructures include nanocrystals, liposomes and lipid nanoparticles, PEGylated polymeric nanodrugs, other polymers, protein-based nanoparticles and metal-based nanoparticles. A range of issues must be addressed in the development of these nanostructures. Ethics, market size, possibility of market failure, costs and commercial development, are some topics which are on the table to be discussed. After passing all the ethical and biological assessments, and satisfying the investors as to future profitability, only a handful of these nanoformulations, successfully obtained marketing approval. We survey the range of nanomedicines that have received regulatory approval and are marketed. We discuss ethics, costs, commercial development and possible market failure. We estimate the global nanomedicine market size and future growth. Our goal is to summarize the different approved nanoformulations on the market, and briefly cover the challenges and future outlook. © 2019 2018 Future Medicine Ltd.